Cargando…
Loading, please waitCargando…
Loading, please waitCondition Guide
A clear, conservative look at mesenchymal stem cell (MSC) therapy as a regenerative option for erectile dysfunction (ED), delivered in Cancún, México under COFEPRIS oversight. What the published clinical evidence shows, what it does not yet show, who is and is not a candidate, and how the Regeneris pathway — free medical evaluation followed by a personalized written quote — actually works.
Mesenchymal stem cell (MSC) therapy for erectile dysfunction is investigational, not an approved cure. The published clinical evidence — small phase 1–2 trials and a 2025 systematic review and meta-analysis — reports short-term improvements in IIEF-5 scores and penile hemodynamics with a favorable safety profile, but high-quality randomized data are still limited. Regeneris Therapy in Cancún, México offers physician-led evaluation under COFEPRIS oversight, no published prices, and a personalized written quote only after a free medical evaluation. ED is often a sign of a deeper vascular, metabolic, or hormonal condition — that workup matters as much as the therapy itself.
Clinical overview
Erectile dysfunction (ED) is the consistent inability to attain or maintain an erection sufficient for satisfactory sexual activity. It is common — and most often a downstream signal of vascular, neurologic, metabolic, hormonal, or psychological disease rather than a problem in isolation. In men with diabetes, vascular disease, post-prostatectomy nerve injury, or chronic medication use, ED frequently appears years before more serious cardiovascular events, which is why a thorough medical workup is the first step at our Cancún clinic — long before any regenerative protocol is discussed.
The most common form. Reduced blood flow to penile tissue — driven by atherosclerosis, hypertension, diabetes, or smoking — limits the hemodynamic response needed for an erection. Standard care includes PDE5 inhibitors; some men become non-responders.
What the research shows
"Stem cell therapy for ED" is not one evidence category. Most published human work to date consists of small, single-arm, or open-label phase 1–2 trials — promising for safety and short-term function, but not yet conclusive for efficacy. A 2025 systematic review and meta-analysis summarized the clinical landscape, and a 2025 mechanistic review summarized what MSCs may be doing in penile tissue. We report that gradient honestly here, rather than implying the therapy is approved or curative.
Senel and colleagues reviewed clinical trials of stem cell therapy for ED published between 2000 and May 2024, including eleven studies with six in the meta-analysis. Most studies reported improvements in erectile function at six months across IIEF-5, IIEF erectile-function domain, erectile hardness score, and peak systolic velocity. The authors concluded that outcomes are promising but evidence is not yet conclusive, with only one randomized controlled trial published to date — pending larger, multicenter trials with longer follow-up and standardized protocols.
Candidate screening
Candidacy for an MSC protocol for ED is decided in the medical evaluation, not on a website. The lists below describe the kinds of cases where a regenerative discussion is reasonable, and the situations where therapy is deferred or declined. They are general orientation — your physician in Cancún confirms or rules things out based on your actual workup.
Regulation & location
Regeneris Therapy operates in Cancún, Quintana Roo, México, under the federal oversight of COFEPRIS — Mexico's health regulatory authority, the functional equivalent of the U.S. FDA. Regenerative protocols including MSC therapy are delivered as physician-supervised, investigational care within that legal framework. There is no "stem-cell tourism" loophole here: the same federal rules that apply to a major hospital apply to our Cancún clinic.
Clinic operating notice on file with COFEPRIS (Aviso Sanitario 2323025036X00098) — the federal authorization framework under which advertised regenerative procedures may be offered in Cancún.
How we work
There is no published price for MSC therapy for ED on this page, in any brochure, or over the phone — because there is no honest fixed price. Cell source, dose, route, number of applications, and concomitant care all depend on your evaluation. Our model is a free medical evaluation in Cancún (in person or by secure tele-consult for international patients), followed by a personalized written quote only if and when a protocol is recommended.
Send your history, recent labs, hormone panel, any cardiovascular workup, and your medication list. A licensed physician at our Cancún clinic reviews the case and either recommends a protocol, recommends further workup, or honestly tells you regenerative therapy is not the right tool for you.
If a protocol is appropriate, you receive a written quote with the cell source, dose, route, number of applications, and the medical reasoning behind each. No price appears until your case has been individually reviewed — never before.
Treatment is delivered at our Cancún facility under physician supervision. Follow-up — including IIEF-5 scoring, hemodynamic reassessment when indicated, and ongoing medical management of the underlying drivers of your ED — is part of the plan, not an upsell.
Honest expectations
The single most important thing on this page: MSC therapy for ED is investigational. The published clinical signal at six months is real but modest, the long-term durability data are limited, and individual responses vary widely. We frame outcomes that way deliberately — overpromising is both unethical and a violation of the COFEPRIS advertising framework we work under in Cancún.
FAQ
The questions patients ask us most when considering stem cell therapy for erectile dysfunction at our Cancún, México clinic.
No. Mesenchymal stem cell (MSC) therapy for ED is investigational, not an approved cure. The published clinical evidence — including a 2025 systematic review and meta-analysis (Senel et al., BMC Urology) and a 2024 phase 2 trial in diabetic ED (Al Demour et al., Basic and Clinical Andrology) — reports short-term improvements in IIEF-5 and penile hemodynamics with a favorable safety profile, but high-quality randomized data are limited and only one randomized controlled trial has been published. We discuss it as a regenerative option that may help in well-selected cases, not as a guaranteed cure, at our Cancún clinic.
This page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for erectile dysfunction is investigational; outcomes vary by patient, condition, and protocol, and no regenerative therapy is a guaranteed cure for ED. Treatment decisions require an individualized evaluation with a licensed physician at our Cancún clinic; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your history, recent labs, hormone panel, and any cardiovascular workup. A physician at our Cancún clinic will review your case and tell you honestly whether stem cell therapy fits — with a personalized written quote after your free medical evaluation.
Cavernous nerve injury after radical prostatectomy, pelvic surgery, spinal cord injury, or advanced diabetes can impair the signaling required for erection — a setting in which several MSC trials have focused.
Low testosterone, thyroid disease, and metabolic syndrome contribute or compound. These are screened, treated, and optimized first — regenerative therapy is never a substitute for correcting an identifiable underlying cause.
ED is a symptom with many possible drivers. A serious evaluation in Cancún looks at the whole picture — cardiovascular risk, hormones, medications, mental health, and partner factors — before discussing whether MSC therapy is even an appropriate consideration for your specific case.
Al Demour and colleagues followed eight diabetic men with ED for 24 months after two intracavernous injections of autologous bone-marrow MSCs. The treatment was safe and well tolerated, with only minor, short-term local effects related to the bone-marrow aspiration and injection. This open-label phase 2 design supports a safety signal in a difficult-to-treat ED subgroup; it is not a randomized efficacy trial.
A 2025 review in Stem Cell Research & Therapy summarized current insights into MSC mechanisms in ED: tissue repair, reduction of inflammation, and signaling that may help regenerate smooth muscle and endothelial cells in the corpora cavernosa. The authors frame MSC therapy as a promising regenerative strategy that still requires confirmation in larger, well-controlled human trials before it can be considered an established treatment.
The honest read: the evidence is encouraging on safety and short-term hemodynamic and IIEF-5 improvement, while still preliminary on durability and long-term efficacy. MSC therapy for ED at Regeneris in Cancún is offered investigationally, under physician supervision, with that uncertainty explicitly disclosed — never as a guaranteed cure.
If any of the deferral situations applies to you, it does not necessarily rule therapy out forever — it means the next step is medical optimization with your treating physicians, not an injection.
Advertising notice on file (Aviso de Publicidad 2323022002A00053) — meaning regenerative therapy information presented to patients in Cancún is registered with the regulator, not unregulated marketing.
Care is delivered in person at our Cancún, México facility — never as a remote prescription, mail-order kit, or unsupervised stack. International patients travel to Cancún for evaluation and treatment.
Choosing a clinic in Cancún, México does not mean choosing less oversight — it means choosing physician-led, COFEPRIS-regulated regenerative care delivered in a recognized medical-tourism city with strong logistics for patients from the U.S. and Canada.
If a clinic quotes you a price for stem cell therapy for ED before reviewing your case, that is a marketing decision, not a medical one. Regeneris does the opposite, by design, in Cancún.
Honest framing protects you: it lets you decide based on the actual evidence, not on a sales pitch. That is the standard we hold ourselves to in Cancún.
Delivery is physician-led under COFEPRIS oversight in Cancún, México. The exact route — intracavernosal injection, systemic infusion, or a combination — and the cell source and dose are individualized in your evaluation. There is no fixed package. Treatment is always preceded by a workup of vascular, metabolic, and hormonal contributors to your ED, and is followed by structured follow-up including IIEF-5 reassessment.
Possibly. Diabetic ED and post-prostatectomy ED are two of the populations most studied in published MSC-for-ED clinical trials, and a 24-month phase 2 trial in diabetic men reported a favorable safety profile (Al Demour et al., 2024). Candidacy still requires stable cardiovascular health, optimized diabetes, and a thorough workup — all confirmed in your evaluation at our Cancún clinic, not assumed from the diagnosis alone.
Regeneris does not publish prices for stem cell therapy — not for ED, not for any indication. The reason is medical and ethical: cell source, dose, route, number of applications, and any concomitant care all depend on your individual evaluation, so a fixed online price would either misrepresent the case or pressure a sale. Our model is a free medical evaluation in Cancún (in person or by secure tele-consult), followed by a personalized written quote only if a protocol is recommended.
When responses are reported in the published literature, they are typically measured over weeks to months — IIEF-5 and hemodynamic improvements are most often reported at three- and six-month timepoints. Durability beyond 12–24 months is an open research question with limited long-term data. We discuss your expected timeline honestly in the evaluation, including what we can and cannot predict for your specific case.
Across the published clinical trials summarized in the 2025 BMC Urology systematic review (Senel et al.) and in the 24-month phase 2 follow-up by Al Demour et al. (2024), MSC therapy for ED has shown a favorable short-term safety profile, with adverse events typically limited to minor, short-term local effects related to the procedure itself. That said, MSC therapy is investigational, individual risk depends on your overall medical picture, and our Cancún physicians screen carefully before recommending any protocol. Anyone telling you the therapy is risk-free is overstating the evidence.
How COFEPRIS oversight, lab certification, and physician supervision shape what "safe" means for regenerative care in Cancún.